Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor (TNF), was the first biologic approved for the treatment of moderate to severe inflammatory bowel disease (IBD) in adults over 20 years ago [35, 36]. This evidence concerns the gene TNF and inflammatory bowel disease.